UroGen Pharma Ltd. (URGN)
NASDAQ: URGN · Real-Time Price · USD
11.20
-0.25 (-2.18%)
At close: Mar 28, 2025, 4:00 PM
11.35
+0.15 (1.34%)
After-hours: Mar 28, 2025, 5:21 PM EDT
UroGen Pharma Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for UroGen Pharma stock have an average target of 40.75, with a low estimate of 25 and a high estimate of 55. The average target predicts an increase of 263.84% from the current stock price of 11.20.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for UroGen Pharma stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 5 | 5 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $25 | Strong Buy | Maintains | $25 | +123.21% | Mar 13, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $64 → $55 | Strong Buy | Maintains | $64 → $55 | +391.07% | Mar 11, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $25 | Strong Buy | Maintains | $25 | +123.21% | Mar 10, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $64 | Strong Buy | Reiterates | $64 | +471.43% | Feb 25, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $25 | Strong Buy | Maintains | $25 | +123.21% | Feb 20, 2025 |
Financial Forecast
Revenue This Year
129.81M
from 90.40M
Increased by 43.60%
Revenue Next Year
264.52M
from 129.81M
Increased by 103.77%
EPS This Year
-2.93
from -2.96
EPS Next Year
-0.63
from -2.93
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 159.7M | 411.1M | 741.7M | ||
| Avg | 129.8M | 264.5M | 504.0M | ||
| Low | 101.6M | 176.9M | 301.0M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 76.7% | 216.7% | 180.4% | ||
| Avg | 43.6% | 103.8% | 90.5% | ||
| Low | 12.4% | 36.3% | 13.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.80 | 2.14 | 4.24 | ||
| Avg | -2.93 | -0.63 | 1.67 | ||
| Low | -3.64 | -2.03 | -0.27 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.